Rasagiline (cas 136236-51-6) in Parkinson's Disease
-
Add time:09/05/2019 Source:sciencedirect.com
It has long been recognized that monoamine oxidase (MAO) inhibitors have a role in the management of Parkinson's disease (PD). The MAO‐B inhibitor Rasagiline (cas 136236-51-6) has neuroprotective effects in animal models, mediated partly by its antiapoptotic activity. Rasagiline has been shown to be effective as monotherapy for early PD and as an adjunct to dopaminergic therapy. Clinical trials have also shown putative disease-modifying effects, though rasagiline's potential to alter the long-term course of PD remains controversial. Given the demonstrated benefits of rasagiline, along with its safety and tolerability profile, it has an important role to play in PD therapy.
We also recommend Trading Suppliers and Manufacturers of Rasagiline (cas 136236-51-6). Pls Click Website Link as below: cas 136236-51-6 suppliers
Prev:Short communicationSimultaneous bioanalysis of Rasagiline (cas 136236-51-6) and its major metabolites in human plasma by LC–MS/MS: Application to a clinical pharmacokinetic study
Next:Research ReportRasagiline (cas 136236-51-6) prevents neurodegeneration in thiamine deficient rats—A longitudinal MRI study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Regular articleEffect of long-term treatment with Rasagiline (cas 136236-51-6) on cognitive deficits and related molecular cascades in aged mice09/07/2019
- Research ReportRasagiline (cas 136236-51-6) prevents neurodegeneration in thiamine deficient rats—A longitudinal MRI study09/06/2019
- Short communicationSimultaneous bioanalysis of Rasagiline (cas 136236-51-6) and its major metabolites in human plasma by LC–MS/MS: Application to a clinical pharmacokinetic study09/04/2019
- Protective effect of Rasagiline (cas 136236-51-6) in aminoglycoside ototoxicity09/03/2019
- Chemoenzymatic synthesis of Rasagiline (cas 136236-51-6) mesylate using lipases09/02/2019
- Original research articleEssential difference between the pharmacological spectrum of (−)-deprenyl and Rasagiline (cas 136236-51-6)09/01/2019
- Case ReportRasagiline (cas 136236-51-6) induced hypersexuality in Parkinson’s disease08/31/2019
- Data articleSynthesis and characterization of 1-pyrindane derivatives as Rasagiline (cas 136236-51-6) analogues08/30/2019
- Rasagiline (cas 136236-51-6) monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan08/29/2019